Statin-Associated Muscle Symptoms: Identification and Recommendations for Management
Purpose of Review Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper reviews recommendations for identification and manag...
Gespeichert in:
| Veröffentlicht in: | Current atherosclerosis reports 2024-12, Vol.27 (1), p.5, Article 5 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 5 |
| container_title | Current atherosclerosis reports |
| container_volume | 27 |
| creator | Maki, Kevin C. Kirkpatrick, Carol F. Cheeley, Mary Katherine Jacobson, Terry A. |
| description | Purpose of Review
Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper reviews recommendations for identification and management of patients with SAMS.
Recent Findings
The National Lipid Association and other professional societies have issued guidance to assist clinicians in identifying and managing patients with partial or complete statin intolerance. The most common reason for intolerance is SAMS. This review discusses strategies to achieve therapeutic objectives for atherogenic lipoprotein management in patients with SAMS.
Summary
Many patients who experience SAMS can tolerate some degree of statin therapy and non-statin medications are available as adjunctive or alternative treatments. With a thorough clinician-patient discussion and shared decision-making, a treatment plan can be identified to achieve therapeutic objectives and reduce the risk of atherosclerotic cardiovascular disease. |
| doi_str_mv | 10.1007/s11883-024-01246-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3129689066</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3129689066</sourcerecordid><originalsourceid>FETCH-LOGICAL-c228t-b81b11e9cb579fb8bf6299ed0da017aaaa38f4f05f8a99e0dc3602d6676205b83</originalsourceid><addsrcrecordid>eNp9kE1PAjEURRujEUT_gAszSzfV13amdNwR4gcJxERw3XT6QYYwLU5nFvx7C6hLu2lze95N3kHolsADARg_RkKEYBhojoHQnOP9GRqSguWY05yeH96UYSYgH6CrGDcAFAQnl2jAyqLgVJRDtFp2qqs9nsQYdK06a7JFH_XWZst9s-tCE5-ymbG-q12tExl8przJPqwOTWO9OUYxc6HNFsqrtU1hd40unNpGe_Nzj9Dny_Nq-obn76-z6WSONaWiw5UgFSG21FUxLl0lKsdpWVoDRgEZq3SYcLmDwgmVcjCacaCG8zGnUFSCjdD9qXfXhq_exk42ddR2u1Xehj5KRmjJRQmcJ5SeUN2GGFvr5K6tG9XuJQF5sClPNmWyKY825T4N3f3091Vjzd_Ir74EsBMQ05df21ZuQt_6tPN_td_c9YGg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3129689066</pqid></control><display><type>article</type><title>Statin-Associated Muscle Symptoms: Identification and Recommendations for Management</title><source>MEDLINE</source><source>SpringerLink Journals (MCLS)</source><creator>Maki, Kevin C. ; Kirkpatrick, Carol F. ; Cheeley, Mary Katherine ; Jacobson, Terry A.</creator><creatorcontrib>Maki, Kevin C. ; Kirkpatrick, Carol F. ; Cheeley, Mary Katherine ; Jacobson, Terry A.</creatorcontrib><description>Purpose of Review
Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper reviews recommendations for identification and management of patients with SAMS.
Recent Findings
The National Lipid Association and other professional societies have issued guidance to assist clinicians in identifying and managing patients with partial or complete statin intolerance. The most common reason for intolerance is SAMS. This review discusses strategies to achieve therapeutic objectives for atherogenic lipoprotein management in patients with SAMS.
Summary
Many patients who experience SAMS can tolerate some degree of statin therapy and non-statin medications are available as adjunctive or alternative treatments. With a thorough clinician-patient discussion and shared decision-making, a treatment plan can be identified to achieve therapeutic objectives and reduce the risk of atherosclerotic cardiovascular disease.</description><identifier>ISSN: 1523-3804</identifier><identifier>ISSN: 1534-6242</identifier><identifier>EISSN: 1534-6242</identifier><identifier>DOI: 10.1007/s11883-024-01246-y</identifier><identifier>PMID: 39556289</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Angiology ; Cardiology ; Cholesterol, LDL - blood ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Medicine ; Medicine & Public Health ; Muscular Diseases - chemically induced ; Muscular Diseases - therapy ; Practice Guidelines as Topic ; Review ; Topical Collection on Statin Drugs</subject><ispartof>Current atherosclerosis reports, 2024-12, Vol.27 (1), p.5, Article 5</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c228t-b81b11e9cb579fb8bf6299ed0da017aaaa38f4f05f8a99e0dc3602d6676205b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11883-024-01246-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11883-024-01246-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39556289$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maki, Kevin C.</creatorcontrib><creatorcontrib>Kirkpatrick, Carol F.</creatorcontrib><creatorcontrib>Cheeley, Mary Katherine</creatorcontrib><creatorcontrib>Jacobson, Terry A.</creatorcontrib><title>Statin-Associated Muscle Symptoms: Identification and Recommendations for Management</title><title>Current atherosclerosis reports</title><addtitle>Curr Atheroscler Rep</addtitle><addtitle>Curr Atheroscler Rep</addtitle><description>Purpose of Review
Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper reviews recommendations for identification and management of patients with SAMS.
Recent Findings
The National Lipid Association and other professional societies have issued guidance to assist clinicians in identifying and managing patients with partial or complete statin intolerance. The most common reason for intolerance is SAMS. This review discusses strategies to achieve therapeutic objectives for atherogenic lipoprotein management in patients with SAMS.
Summary
Many patients who experience SAMS can tolerate some degree of statin therapy and non-statin medications are available as adjunctive or alternative treatments. With a thorough clinician-patient discussion and shared decision-making, a treatment plan can be identified to achieve therapeutic objectives and reduce the risk of atherosclerotic cardiovascular disease.</description><subject>Angiology</subject><subject>Cardiology</subject><subject>Cholesterol, LDL - blood</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Muscular Diseases - chemically induced</subject><subject>Muscular Diseases - therapy</subject><subject>Practice Guidelines as Topic</subject><subject>Review</subject><subject>Topical Collection on Statin Drugs</subject><issn>1523-3804</issn><issn>1534-6242</issn><issn>1534-6242</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1PAjEURRujEUT_gAszSzfV13amdNwR4gcJxERw3XT6QYYwLU5nFvx7C6hLu2lze95N3kHolsADARg_RkKEYBhojoHQnOP9GRqSguWY05yeH96UYSYgH6CrGDcAFAQnl2jAyqLgVJRDtFp2qqs9nsQYdK06a7JFH_XWZst9s-tCE5-ymbG-q12tExl8przJPqwOTWO9OUYxc6HNFsqrtU1hd40unNpGe_Nzj9Dny_Nq-obn76-z6WSONaWiw5UgFSG21FUxLl0lKsdpWVoDRgEZq3SYcLmDwgmVcjCacaCG8zGnUFSCjdD9qXfXhq_exk42ddR2u1Xehj5KRmjJRQmcJ5SeUN2GGFvr5K6tG9XuJQF5sClPNmWyKY825T4N3f3091Vjzd_Ir74EsBMQ05df21ZuQt_6tPN_td_c9YGg</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Maki, Kevin C.</creator><creator>Kirkpatrick, Carol F.</creator><creator>Cheeley, Mary Katherine</creator><creator>Jacobson, Terry A.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241201</creationdate><title>Statin-Associated Muscle Symptoms: Identification and Recommendations for Management</title><author>Maki, Kevin C. ; Kirkpatrick, Carol F. ; Cheeley, Mary Katherine ; Jacobson, Terry A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c228t-b81b11e9cb579fb8bf6299ed0da017aaaa38f4f05f8a99e0dc3602d6676205b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Angiology</topic><topic>Cardiology</topic><topic>Cholesterol, LDL - blood</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Muscular Diseases - chemically induced</topic><topic>Muscular Diseases - therapy</topic><topic>Practice Guidelines as Topic</topic><topic>Review</topic><topic>Topical Collection on Statin Drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maki, Kevin C.</creatorcontrib><creatorcontrib>Kirkpatrick, Carol F.</creatorcontrib><creatorcontrib>Cheeley, Mary Katherine</creatorcontrib><creatorcontrib>Jacobson, Terry A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current atherosclerosis reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maki, Kevin C.</au><au>Kirkpatrick, Carol F.</au><au>Cheeley, Mary Katherine</au><au>Jacobson, Terry A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statin-Associated Muscle Symptoms: Identification and Recommendations for Management</atitle><jtitle>Current atherosclerosis reports</jtitle><stitle>Curr Atheroscler Rep</stitle><addtitle>Curr Atheroscler Rep</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>27</volume><issue>1</issue><spage>5</spage><pages>5-</pages><artnum>5</artnum><issn>1523-3804</issn><issn>1534-6242</issn><eissn>1534-6242</eissn><abstract>Purpose of Review
Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper reviews recommendations for identification and management of patients with SAMS.
Recent Findings
The National Lipid Association and other professional societies have issued guidance to assist clinicians in identifying and managing patients with partial or complete statin intolerance. The most common reason for intolerance is SAMS. This review discusses strategies to achieve therapeutic objectives for atherogenic lipoprotein management in patients with SAMS.
Summary
Many patients who experience SAMS can tolerate some degree of statin therapy and non-statin medications are available as adjunctive or alternative treatments. With a thorough clinician-patient discussion and shared decision-making, a treatment plan can be identified to achieve therapeutic objectives and reduce the risk of atherosclerotic cardiovascular disease.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>39556289</pmid><doi>10.1007/s11883-024-01246-y</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3804 |
| ispartof | Current atherosclerosis reports, 2024-12, Vol.27 (1), p.5, Article 5 |
| issn | 1523-3804 1534-6242 1534-6242 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3129689066 |
| source | MEDLINE; SpringerLink Journals (MCLS) |
| subjects | Angiology Cardiology Cholesterol, LDL - blood Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Medicine Medicine & Public Health Muscular Diseases - chemically induced Muscular Diseases - therapy Practice Guidelines as Topic Review Topical Collection on Statin Drugs |
| title | Statin-Associated Muscle Symptoms: Identification and Recommendations for Management |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T02%3A50%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statin-Associated%20Muscle%20Symptoms:%20Identification%20and%20Recommendations%20for%20Management&rft.jtitle=Current%20atherosclerosis%20reports&rft.au=Maki,%20Kevin%20C.&rft.date=2024-12-01&rft.volume=27&rft.issue=1&rft.spage=5&rft.pages=5-&rft.artnum=5&rft.issn=1523-3804&rft.eissn=1534-6242&rft_id=info:doi/10.1007/s11883-024-01246-y&rft_dat=%3Cproquest_cross%3E3129689066%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3129689066&rft_id=info:pmid/39556289&rfr_iscdi=true |